Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.52 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8739516 | 1.00 | ALDH1A1 (0.64) | ALDH1A1CYP3A4TP53LMNAGAA | |
| SCHEMBL1528011 | 1.00 | ALDH1A1 (0.64) | ALDH1A1CYP3A4TP53LMNAGAA | |
| SCHEMBL1605115 | 1.00 | ALDH1A1 (0.64) | ALDH1A1CYP3A4TP53LMNAGAA | |
| SCHEMBL1475935 | 0.97 | — | — | |
| SCHEMBL2257067 | 0.92 | — | — | |
| SCHEMBL1473973 | 0.86 | — | — | |
| SCHEMBL3075189 | 0.83 | ALDH1A1 (0.70) | ALDH1A1CYP3A4TP53LMNAGAA | |
| SCHEMBL3068524 | 0.82 | SMN1; SMN2 (0.61) | ALDH1A1CYP3A4TP53LMNAGAA | |
| SCHEMBL23591882 | 0.81 | ALDH1A1 (0.43) | ALDH1A1CYP3A4TP53LMNAGAA | |
| SCHEMBL3206894 | 0.80 | ALDH1A1 (0.58) | ALDH1A1CYP3A4TP53LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118086316-B | Use of nucleotides of lactobacillus rhamnosus for preparing anti-adipogenic composition | GENMONT BIOTECH INC. (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-12576101-B2 | Application based nucleotides of Lactobacillus rhamnosus to prepare a composition for anti-lipogenesis | GENMONT BIOTECH INCORPORATION (TW) | 2026-03-17 | — | — | US | disclosed |
| US-20250249028-A1 | APPLICATION BASED ON NUCLEOTIDES OF LACTOBACILLUS RHAMNOSUS TO PREPARE A COMPOSITION FOR ANTI-LIPOGENESIS | GENMONT BIOTECH INCORPORATION (TW) | 2025-08-07 | — | — | US | disclosed |
| US-12233107-B2 | GHRH or analogues thereof for use in treatment of hepatic disease | THE GENERAL HOSPITAL CORPORATION (US) | 2025-02-25 | — | — | US | disclosed |
| CN-118086316-A | Use of nucleotides of lactobacillus rhamnosus for preparing anti-adipogenic composition | 景岳生物科技股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240091316-A1 | GHRH OR ANALOGUES THEREOF FOR USE IN TREATMENT OF HEPATIC DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2024-03-21 | — | — | US | disclosed |
| US-11738066-B2 | GHRH or analogues thereof for use in treatment of hepatic disease | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-29 | — | — | US | disclosed |
| EP-3947426-A1 | GHRH OR ANALOGUES THEREOF FOR USE IN TREATMENT OF HEPATIC DISEASE | The General Hospital Corporation (US) | 2022-02-09 | — | — | EP | disclosed |
| US-9353089-B2 | Compositions and methods for the treatment of malaria | SAINT LOUIS UNIVERSITY (US) | 2016-05-31 | — | — | US | disclosed |
| WO-2014160775-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MALARIA | SAINT LOUIS UNIVERSITY (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2007-08-23 | — | — | US | disclosed |
| US-7253196-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| WO-2007061661-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1753736-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | Amgen Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2005116002-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12233107-B2 | GHRH or analogues thereof for use in treatment of hepatic disease | HDGF, HGF, HDGFL3 | ALDH1A1 2620/4885CYP3A4 3704/4885TP53 2394/4885 |
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | ALDH1A1 67/4885CYP3A4 78/4885TP53 4022/4885 |
| US-11738066-B2 | GHRH or analogues thereof for use in treatment of hepatic disease | HDGF, HGF, HDGFL3 | ALDH1A1 2620/4885CYP3A4 3704/4885TP53 2394/4885 |
| US-12576101-B2 | Application based nucleotides of Lactobacillus rhamnosus to prepare a composition for anti-lipogenesis | FABP4, LIPC, CPT1B | ALDH1A1 2581/4885CYP3A4 2117/4885TP53 3912/4885 |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | ALDH1A1 71/4885CYP3A4 280/4885TP53 3747/4885 |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD17B1 | ALDH1A1 100/4885CYP3A4 158/4885TP53 4088/4885 |
| US-20240091316-A1 | GHRH OR ANALOGUES THEREOF FOR USE IN TREATMENT OF HEPATIC DISEASE | HDGF, HGF, HDGFL3 | ALDH1A1 2620/4885CYP3A4 3704/4885TP53 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.